Company Overview of Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marin...
Three Radnor Corporate Center
100 Matsonford Road
Radnor, PA 19087
Founded in 2003
Key Executives for Marinus Pharmaceuticals, Inc.
Executive Chairman, Chief Executive Officer and President
Total Annual Compensation: $455.0K
Chief Financial Officer, Vice President, Treasurer and Secretary
Total Annual Compensation: $405.0K
Chief Clinical Development & Regulatory Officer
Total Annual Compensation: $358.9K
Compensation as of Fiscal Year 2014.
Marinus Pharmaceuticals, Inc. Key Developments
Marinus Pharmaceuticals, Inc., Annual General Meeting, Apr 21, 2015
Mar 17 15
Marinus Pharmaceuticals, Inc., Annual General Meeting, Apr 21, 2015., at 09:30 US Eastern Standard Time. Location: The NASDAQ MarketSite, 4 Times Square, 2nd Floor. Agenda: To consider the election of two Class I director nominees; to ratify the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
Marinus Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Year Ended December 31, 2014
Mar 12 15
Marinus Pharmaceuticals, Inc. reported unaudited earnings results for the year ended December 31, 2014. The company reported net losses of $10.8 million and $5.3 million for the years ended December 31, 2014 and 2013, respectively. Cash used in operating activities was $8.6 million compared to $6.6 million for the same period a year ago. Loss from operations was $11.9 million against $5.4 million a year ago. Net loss applicable to common stockholders $13.4 million against $9.1 million a year ago. Net loss per share of common stock - basic and diluted was $2.17 against $19.60 a year ago.
Marinus Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:00 AM
Feb 26 15
Marinus Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:00 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|